Marker Therapeutics, Inc. (MRKR)

Market Cap	24.89M
Revenue (ttm)	9.06M
Net Income (ttm)	-9.29M
Shares Out	8.89M
EPS (ttm)	-1.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	642
Open	2.78
Previous Close	2.82
Day's Range	2.78 - 2.80
52-Week Range	0.67 - 9.68
Beta	1.33
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 9, 2023

About MRKR

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and sel...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Juan F. Vera M.D.
• Employees: 67
• Stock Exchange: NASDAQ
• Ticker Symbol: MRKR

Financial Performance

In 2022, MRKR's revenue was $9.01 million, an increase of 625.90% compared to the previous year's $1.24 million. Losses were -$29.93 million, -28.53% less than in 2021.